Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 1(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02280421Phase 1Completed

Drug-Drug Interaction Study: ASP2151 and Ciclosporin

Role: lead

NCT02223351Phase 1Completed

Drug-Drug Interaction Study: ASP2151 and Ritonavir

Role: lead

NCT02321748Phase 1Completed

Drug-Drug Interaction Study: ASP2151 and Montelukast

Role: lead

NCT02369172Phase 1Completed

Drug-Drug Interaction Study: ASP2151 and Bupropion

Role: lead

NCT02403635Phase 1Completed

Drug-Drug Interaction Study: ASP2151 and Midazolam

Role: lead

NCT01989429Phase 3Completed

Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients

Role: lead

All 6 trials loaded